Dialyzability and binding of digoxin-like immunoreactive factors (DLIF) with serum macromolecules in uremic patients on hemodialysis

Hemodialyzability of ionizable fluoride in hemodialysis session

The fluoride ion content in serum and in dialysate medium was determined by means of a fluoride ion-selective electrode in 29 patients undergoing hemodialysis treatment. Abnormally high serum fluoride of 65.9 +/- 28.3 microg l(-1) at the beginning and 46.5 +/- 26.7 microg l(-1) at the completion of the hemodialysis session was observed. Results showed that 60.0 +/- 23.9% of the serum fluoride at the beginning of the session was theoretically filterable, and 80.8 +/- 42.4% of this fraction was actually filtered throughout the hemodialysis session. The dialysis procedure is considered to be safe and adequate for serum fluoride removal. The high serum fluoride at the completion of the hemodialysis session was thought to originate from the fraction of unfilterable binding fluoride. To make further progress towards improvements in serum fluoride removal during HD, attention to the binding fraction of serum fluoride is required.

Quantitation of interference in digoxin immunoassay in renal, hepatic, and diabetic disease

A comparison of the results of a newly developed fluorescence-derivatization/HPLC method and a commercial immunoassay method (ACA, Dupont) for the measurement of serum digoxin concentrations in patients indicates that (1) the results from the ACA method agree well with those from the HPLC method in patients with cardiovascular disease but without renal, diabetic, and liver disease, (2) serum digoxin concentrations determined by the ACA method are overestimated in patients with renal, diabetic, or liver disease, and (3) the steady-state serum concentrations of hydrolyzed and reduced metabolites are relatively insignificant in patients receiving digoxin therapy, including patients with renal failure. The excellent reproducibility of the HPLC and immunoassay methods (coefficient of variation < 9.0%), together with the demonstrated specificity of the HPLC method with respect to potential interference from digoxin metabolites, endogenous digoxin-like immunoactive substances, and coadministered drugs and their metabolites, allows quantitation of the degree of interference in digoxin immunoassays under actual therapeutic drug monitoring conditions. Clinically significant interferences (0.3 to 1.1 ng/ml) with immunoassay determination were found in the majority of patients in all three diseases studied.